InvestorsHub Logo
Followers 8
Posts 1923
Boards Moderated 0
Alias Born 09/10/2012

Re: None

Friday, 12/17/2021 1:54:49 AM

Friday, December 17, 2021 1:54:49 AM

Post# of 326
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

-European Commission Decision Anticipated in Q1 2022-

-CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration-
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OBSV News